Patients aged 18 to 85 years with chronic plaque-type psoriasis , a minimum Physician Global Assessment score of 3 ( higher scores indicate more severe disease ) , and a psoriatic plaque of at least 2 cm were randomized in a 1:1 fashion to receive subcutaneous adalimumab or oral methotrexate .